Overview
Updated 14 Jul 2026
Bruce Trapnell, MD, is affiliated with Cincinnati Children's Hospital Medical Center. The public record shows 316 publications with 20,982 citations (h-index 81), centered on Neonatal Respiratory Health Research, Virus-based gene therapy research, Congenital Diaphragmatic Hernia Studies. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 7 companies, 15 NIH-funded awards (1995–2025).
- Most recent indexed publication: 2026 · European respiratory review
- Top research focus: Neonatal Respiratory Health Research
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 177.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Sponsor: Savara Inc.
InvestigatorPhase 3Active, not recruitingNCT04544293 - The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis
Sponsor: Children's Hospital Medical Center, Cincinnati
InvestigatorCompletedNCT03531996 - Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
Sponsor: Children's Hospital Medical Center, Cincinnati
InvestigatorPhase 1CompletedNCT03231033
Industry payments
Updated 14 Jul 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Kyowa Kirin Co., LtdProgram year20252 payments
- La Jolla Pharmaceutical CompanyProgram year20251 payment
- Partner Therapeutics, Inc.Program year20246 payments$15,261openpaymentsdata.cms.gov ↗
NIH funding
Updated 14 Jul 2026
15 NIH research awards on record, funded 1995–2025 per NIH RePORTER. The latest:
- Technology to understand genetic variant effects in context
University of Washington
FY2026$2,128,294RM1HG010461 - Versatile, exponentially scalable methods for single cell molecular profiling
University of Washington
FY2026$655,233R01HG010632 - Technology to understand genetic variant effects in context
University of Washington
FY2025$2,128,294RM1HG010461
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The burden of autoimmune pulmonary alveolar proteinosis: a systematic review.
European respiratory review
2026 - Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.
The New England journal of medicine
2025 - Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
Arthritis & rheumatology (Hoboken, N.J.)
2022
Most-cited worksby citation count (OpenAlex)
- 01Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis1,116 citations2011
- 02
- 03Pulmonary Alveolar Proteinosis790 citations2003
- 04
- 05
Contact
No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this specialty yet.